5. Variable target of rapamycin inhibitors (TOR‐I) and calcineurin inhibitors (CNI): comparison in outcomes between 2006 review and 2019 update.
| Outcome | 2006 review (8 studies) | 2019 update (9 studies) |
| Death | No difference | No difference |
| All graft loss | No difference | No difference |
| Graft loss censored for death | No difference | No difference |
| All acute rejection | Reduced in low TOR‐I | No difference |
| Biopsy‐proven acute rejection | Reduced in low TOR‐I | No difference |
| CMV infection | No difference | No difference |
| Wound complications | No difference | No difference |
| Malignancies | No difference | No difference |
| Need to change treatment | No difference | No difference |
| New‐onset diabetes mellitus | No difference | No difference |
| Lymphoma/PTLD | No difference | No difference |
| BK virus infection | Not reported | No difference |
| Tremor | No difference (1 study) | No difference |
| Acne/rash | Not reported | No difference |
| GFR | Increased in low TOR‐I | Increased in low TOR‐I |
| SCr | No difference | No difference |
| Hypercholesterolaemia | No difference | No difference |
| Hypertriglyceridaemia | No difference | No difference |
| Leucopenia | No difference | No difference |
| Thrombocytopenia | No difference | No difference |
Change in results have been highlighted
CMV ‐ cytomegalovirus; GFR ‐ glomerular filtration rate; PTLD ‐ post‐transplant lymphoproliferative disease; SCr ‐ serum creatinine